Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-23T07:15:50.978Z Has data issue: false hasContentIssue false
  • English
  • Français

A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania

Published online by Cambridge University Press:  18 July 2014

A. Yildiz ,
M. Nikodem ,
E. Vieta ,
C. U. Correll  and
R. J. Baldessarini
A. Yildiz*
Affiliation:
Department of Psychiatry, Dokuz Eylül University, Izmir, Turkey International Consortium for Bipolar Disorder Research & Psychopharmacology Program, McLean Division of Massachusetts General Hospital, Boston, MA, USA
M. Nikodem
Affiliation:
Faculty of Applied Mathematics, AGH University of Science and Technology, Krakow, Poland
E. Vieta
Affiliation:
International Consortium for Bipolar Disorder Research & Psychopharmacology Program, McLean Division of Massachusetts General Hospital, Boston, MA, USA Bipolar Disorders Program, Institute of Clinical Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
C. U. Correll
Affiliation:
Division of Psychiatry Research, Department of Psychiatry, Zucker Hillside Hospital, New York, NY, USA
R. J. Baldessarini
Affiliation:
International Consortium for Bipolar Disorder Research & Psychopharmacology Program, McLean Division of Massachusetts General Hospital, Boston, MA, USA Department of Psychiatry, Harvard Medical School Boston, MA, USA
*
*Address for correspondence: Dr A. Yildiz, Depression & Bipolar Disorders Foundation/Duygudurum Vakfi-DUVAK, Yenikale Mah. Sutculer Sok. No.7/3 Narlidere, Izmir, Turkey. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Evidence synthesis methods enabling direct and indirect comparisons over the entire set of relevant clinical data produce quantitative point estimates for the treatments contrasts between competing interventions, and provide a hierarchical rank ordering between them. We aimed to provide evidence-based guidance on the efficacy and all-cause discontinuation of antimanic treatments.

Method

We conducted a network meta-analysis within a Bayesian framework. We searched all standard literature databases without language restrictions up to 15 January 2014 to identify reports of short-term, randomized, blinded trials of putative antimanic drugs as monotherapy for adults with bipolar-I mania.

Results

Altogether, 14256 manic patients randomized to one of 18 active treatments or placebo provided 95 direct comparisons on 128 data points. For the primary outcome, standardized mean difference as Hedges’ g (standardized mean difference; SMD), the hierarchies indicated by surface under the cumulative ranking (SUCRA) probabilities were in agreement with the point estimates for all antimanic drugs identified as effective. For the 12 effective antimanic drugs on clinical use, SMDs against placebo ranged from 0.32 to 0.66 without superiority of one over another, except for risperidone v. aripiprazole and valproate. Aripiprazole, olanzapine, quetiapine, risperidone, and valproate had less all-cause discontinuation rates than placebo. Sensitivity analysis by drug class indicated similar efficacy profiles for haloperidol, second-generation antipsychotics, and mood stabilizers.

Conclusions

Hierarchical rank ordering by comparative efficacy and risk of all-cause discontinuations should help to guide antimanic treatment choices by clinicians, healthcare policy makers, and guideline developers.

Keywords

All-cause discontinuationsantimanicbipolarmaniamultiple treatments meta-analysis
Type
Original Articles
Information
Psychological Medicine , Volume 45 , Issue 2 , January 2015 , pp. 299 - 317
Copyright
Copyright © Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ades, AE, Sculpher, M, Sutton, A, Abrams, K, Cooper, N, Welton, N, Lu, G (2006). Bayesian methods for evidence aynthesis in cost-effectiveness analysis. Pharmacoeconomics 24, 1–19.Google Scholar
Ades, AE, Welton, N, Lu, G. Introduction to Mixed Treatment Comparisons. (https://www.bris.ac.uk/cobm/research/mpes/mtc.html). Accessed 20 January 2014.Google Scholar
Ahrens, B, Müller-Oerlinghausen, B, Schou, M, Wolf, T, Alda, M, Grof, E, Grof, P, Lenz, G, Simhandl, C, Thau, K, Volk, J, Wolf, R, Wolf, T (1995). Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. Journal of Affective Disorders 33, 67–75.CrossRefGoogle ScholarPubMed
Altman, DG (1998). Confidence intervals for the number needed to treat. British Medical Journal 317, 1309–1312.CrossRefGoogle ScholarPubMed
American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. text revision. APA: Washington, DC.Google Scholar
Bachmann, RF, Wang, Y, Yuan, P, Zhou, R, Li, X, Alesci, S, Du, J, Manji, HK (2009). Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. International Journal of Neuropsychopharmacology 12, 805–822.Google Scholar
Baldessarini, RJ (2013). Chemotherapy in Psychiatry, 3rd edn. Springer Press: New York, NY.Google Scholar
Beigel, A, Murphy, DL (1971). Assessing clinical characteristics of the manic state. American Journal of Psychiatry 128, 688–694.CrossRefGoogle ScholarPubMed
Bose, A, Starace, A, Wang, Q, Diaz, E, Goodman, J, Ruth, A, Németh, G, Laszlovszky, I (2012). Cariprazine in the treatment of acute mania in bipolar disorder: a double-blind, placebo-controlled, phase III trial. ClinicalTrials.gov: NCT01058096. European Neuropsychopharmacology 22 (Suppl. 2), S285.Google Scholar
Bowden, CL, Göğüş, A, Grunze, H, Häggström, L, Rybakowski, J, Vieta, E (2008). 12-week, open, randomized trial comparing sodium valproate to lithium in patients with bipolar I disorder suffering from a manic episode. International Journal of Clinical Psychopharmacology 23, 254–262.Google Scholar
Bowden, CL, Mosolov, S, Hranov, L, Chen, E, Habil, H, Kongsakon, R, Manfredi, R, Lin, HN (2010). Efficacy of valproate vs. lithium in mania or mixed mania: randomized, open 12-week trial. International Journal of Clinical Psychopharmacology 25, 60–67.CrossRefGoogle ScholarPubMed
Brown, D, Silverstone, T, Cookson, J (1989). Carbamazepine compared to haloperidol in acute mania. International Journal of Clinical Psychopharmacology 4, 229–238.Google Scholar
Calabrese, JR, Keck, PE Jr., Starace, A, Lu, K, Ruth, A, Laszlovszky, I, Nemeth, G, Durgam, S (2013). Efficacy and safety of low- and high-dose cariprazine in patients with acute mania associated with bipolar I disorder. ClinicalTrials.gov: NCT01058668. European Neuropsychopharmacology 23 (Suppl. 2), S378–S379.Google Scholar
Caldwell, DM, Ades, AE, Higgins, JP (2005). Simultaneous comparison of multiple treatments: combining direct and indirect evidence. British Medical Journal 331, 897–900.Google Scholar
Centorrino, F, Masters, GA, Talamo, A, Baldessarini, RJ, Öngür, D (2012). Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. Human Psychopharmacology 27, 521–526.Google Scholar
Chaimani, C, Salanti, G (2012). Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Research Synthesis Methods 3, 161–176.CrossRefGoogle Scholar
Chang, CK, Hayes, RD, Perera, G, Broadbent, MT, Fernandes, AC, Lee, WE, Hotopf, M, Stewart, R (2011). Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS ONE 6, e19590.Google Scholar
Chinn, S (2000). Simple method for converting an odds ratio to effect size for use in meta-analysis. Statistics in Medicine 19, 3127–3131.3.0.CO;2-M>CrossRefGoogle ScholarPubMed
Cipriani, A, Barbui, C, Salanti, G, Rendell, J, Brown, R, Stockton, S, Purgato, M, Spineli, LM, Goodwin, GM, Geddes, JR (2011). Comparative efficacy and acceptability of antimanic drugs in acute mania: multiple-treatments meta-analysis. Lancet 378, 1306–1315.CrossRefGoogle ScholarPubMed
Cipriani, A, Furukawa, TA, Salanti, G, Geddes, JR, Higgins, JP, Churchill, R, Watanabe, N, Nakagawa, A, Omori, IM, McGuire, H, Tansella, M, Barbui, C (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373, 746–758.CrossRefGoogle ScholarPubMed
Cipriani, A, Hawton, K, Stockton, S, Geddes, JR (2013). Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. British Medical Journal 346, f3646.CrossRefGoogle ScholarPubMed
Dias, S, Welton, NJ, Caldwell, DM, Ades, AE (2010). Checking consistency in mixed treatment comparison meta-analysis. Statistics in Medicine 29, 932–944.Google Scholar
Drevets, WC, Price, JL, Simpson, JR Jr., Todd, RD, Reich, T, Vannier, M, Raichle, ME (1997). Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386, 824–827.Google Scholar
Eckermann, S, Coory, M, Willan, AR (2009). Indirect comparison: relative risk fallacies and odds solution. Journal of Clinical Epidemiology 62, 1031–1036.Google Scholar
Endicott, J, Spitzer, RL (1978). Diagnostic interview: the schedule for affective disorders and schizophrenia. Achieves of General Psychiatry 35, 837–844.Google Scholar
Freeman, TW, Clothier, JL, Pazzaglia, P, Lesem, MD, Swann, AC (1992). Double-blind comparison of valproate and lithium in the treatment of acute mania. American Journal of Psychiatry 149, 108–111.Google Scholar
Gardner, DM, Murphy, AL, O'Donnell, H, Centorrino, F, Baldessarini, RJ (2010). International consensus study of antipsychotic dosing. American Journal of Psychiatry 167, 686–693.Google Scholar
Garza-Treviño, ES, Overall, JE, Hollister, LE (1992). Verapamil vs. lithium in acute mania. American Journal of Psychiatry 149, 121–122.Google Scholar
Glenny, AM, Altman, DG, Song, F, Sakarovitch, C, Deeks, JJ, D'Amico, R, Bradburn, M, Eastwood, AJ (2005). Indirect comparisons of competing interventions. Health Technology Assessment 9, 1–134.Google Scholar
Goldsmith, DR, Wagstaff, AJ, Ibbotson, T, Perry, CM (2003). Lamotrigine: review of its use in bipolar disorder. Study ID Number: SCAA2008. Drugs 63, 2029–2050.CrossRefGoogle Scholar
Goodwin, RK, Jamison, KR (2007). Manic-Depressive Illness, 2nd edn. Oxford University Press: New York, NY.Google Scholar
Grande, I, Bernardo, M, Bobes, J, Saiz-Ruiz, J, Alamo, C, Vieta, E (2014). Antipsychotic switching in bipolar disorders: a systematic review. International Journal of Neuropsychopharmacology 17, 497–507.Google Scholar
Janicak, PG, Sharma, RP, Pandey, G, Davis, JM (1998). Verapamil for the treatment of acute mania: double-blind, placebo-controlled trial. American Journal of Psychiatry 155, 972–973.Google Scholar
Jonas, D, Wilkins, T, Bangdiwala, S, Bann, C, Morgan, L, Thaler, K, Amick, H, Gartlehner, G (2013). Findings of Bayesian Mixed Treatment Comparison Meta-Analyses, Comparison and Exploration using Real-World Trial data and Simulation. Agency for Healthcare Research and Quality (US), Methods Research Report No. 13-EHC039-EF.Google Scholar
Kakkar, AK, Rehan, HS, Unni, KES, Gupta, NK, Chopra, D, Kataria, D (2009). Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: pilot study. European Psychiatry 24, 178–182.CrossRefGoogle ScholarPubMed
Knesevich, M, Papadakis, K, Bose, A, Andor, G, Laszlovszky, I (2009). The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. ClinicalTrials.gov: NCT00488618. European Neuropsychopharmacology 19 (Suppl. 3), S469.CrossRefGoogle Scholar
Kriston, L, Yildiz, A (in press). Traditional and novel research synthesis approaches to support evidence-based treatment decisions In Bipolar Book: History, Neurobiology, and Treatment (ed. Yildiz, A., Nemeroff, C. and Ruiz, P.). Oxford University Press: New York.Google Scholar
Laursen, TM (2011). Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophrenia Research 131, 101–104.CrossRefGoogle ScholarPubMed
Leboyer, M, Soreca, I, Scott, J, Frye, M, Henry, C, Tamouza, R, Kupfer, DJ (2012). Can bipolar disorder be viewed as a multi-system inflammatory disease? Journal of Affective Disorders 141, 1–10.Google Scholar
Lerer, B, Moore, N, Meyendorff, E, Cho, SR, Gershon, S (1987). Carbamazepine vs. lithium in mania: double-blind study. Journal of Clinical Psychiatry 48, 89–93.Google Scholar
Leucht, S, Cipriani, A, Spineli, L, Mavridis, D, Orey, D, Richter, F, Samara, M, Barbui, C, Engel, RR, Geddes, JR, Kissling, W, Stapf, MP, Lässig, B, Salanti, G, Davis, JM (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382, 951–962.CrossRefGoogle ScholarPubMed
Li, H, Ma, C, Wang, G, Zhu, X, Peng, M, Gu, N (2008). Response and remission rates in Chinese patients with bipolar mania treated for 4 weeks with either quetiapine or lithium: randomized and double-blind study. ClinicalTrials.gov: NCT00448578. Current Medical Research and Opinion 24, 1–10.Google Scholar
Lu, G, Ades, AE (2004). Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine 23, 3105–3124.Google Scholar
Machado-Vieira, R, Manji, HK, Zarate, CA Jr. (2009). The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disorders 11 (Suppl. 2), 92–109.Google Scholar
Mauri, D, Polyzos, NP, Salanti, G, Pavlidis, N, Ioannidis, JP (2008). Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. Journal of the National Cancer Institute 100, 1780–1791.Google Scholar
McElroy, SL, Martens, BE, Creech, RS, Welge, JA, Jefferson, L, Guerdjikova, AI, Keck, PE Jr. (2010 a). Randomized, double-blind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate-to-severe hypomania or mild mania. Journal of Clinical Psychiatry 71, 557–565.Google Scholar
McElroy, SL, Martens, BE, Winstanley, EL, Creech, R, Malhotra, S, Keck, PE Jr. (2010 b). Placebo-controlled study of quetiapine monotherapy in ambulatory bipolar spectrum disorder with moderate-to-severe hypomania or mild mania. Journal of Affective Disorders 124, 157–163.Google Scholar
Merikangas, KR, Akiskal, HS, Angst, J, Greenberg, PE, Hirschfeld, RM, Petukhova, M, Kessler, RC (2007). Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Achieves of General Psychiatry 64, 543–552.Google Scholar
Moreno, SG, Sutton, AJ, Ades, AE, Stanley, TD, Abrams, KR, Peters, JL, Cooper, NJ (2009). Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study. BMC Medical Research Methodology 9, 2.CrossRefGoogle ScholarPubMed
Mosolov, SN, Kostiukova, EG, Kapiletti, SG, Belen'kaia, DV, Shafarenko, AA, Fedotov, DD (2009). Open randomized comparative twelve-week study of lithium and valproate in manic episode [in Russian]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 109, 47–52.Google ScholarPubMed
Mizuno, Y, Suzuki, T, Nakagawa, A, Yoshida, K, Mimura, M, Fleischhacker, WW, Uchida, H (2014). Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: systematic review and meta-analysis. Schizophrenia Bulletin. Published online: 17 March 2014 . PMID: 24636967.Google Scholar
Novartis Clinical Trial Results Database (2007). Randomized, double-blind, placebo-controlled multicenter study to evaluate efficacy and tolerability of licabazepine 1000–2000 mg/d in the treatment of manic episodes of bipolar I disorder over 3 weeks. Study ID Number: CLIC477D2301. ClinicalTrials.gov: NCT00099229 (data on file).Google Scholar
Ortega Soto, HA (1993). Carbamazepine vs haloperidol in treatment of manic episodes: controlled clinical trial. (Spanish) Salud Mental 16, 44–50.Google Scholar
Ösby, U, Brandt, L, Correia, N, Ekbom, A, Sparén, P (2001). Excess mortality in bipolar and unipolar disorder in Sweden. Achieves of General Psychiatry 58, 844–850.Google Scholar
Pfizer Clinical Trial Results Database (2008). Multicenter, randomized, double-blind, parallel group study, comparing the efficacy and tolerability of ziprasidone (Zeldox, Geodon) vs olanzapine (Zyprexa) in the treatment and maintenance of response in patients with acute mania. Study ID Number: A1281147. ClinicalTrials.gov: NCT00329108 (data on file).Google Scholar
Salanti, G, Ades, AE, Ioannidis, JP (2011). Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology 64, 163–171.CrossRefGoogle ScholarPubMed
Salanti, G, Higgins, JPT, Ades, AE, Ioannidis, JPA (2008). Evaluation of networks of randomized trials. Statistical Methods in Medical Research 17, 279–301.Google Scholar
Salanti, G, Marinho, V, Higgins, JPT (2009). Case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. Journal of Clinical Epidemiology 62, 857–864.CrossRefGoogle ScholarPubMed
Shafti, SS (2010). Olanzapine vs. lithium in management of acute mania. Journal of Affective Disorders 122, 273–276.Google Scholar
Shafti, SS, Shahveisi, B (2008). Comparison between lithium and valproate in the treatment of acute mania. Journal of Clinical Psychopharmacology 28, 718–720.Google Scholar
Spiegelhalter, DJ, Best, NG, Carlin, BP, van der Linde, A (2002). Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society 64, 583–639.Google Scholar
Spitzer, RL, Endicott, J, Robins, E (1978). Research diagnostic criteria: rationale and reliability. Archives of General Psychiatry 35, 773–782.Google Scholar
Tondo, L, Lepri, B, Baldessarini, RJ (2007). Risks of suicidal ideation, attempts and suicides among 2826 men and women with types I and II bipolar, and recurrent major depressive disorders. Acta Psychiatrica Scandinavica 116, 419–428.CrossRefGoogle Scholar
Vasudev, K, Goswami, U, Kohli, K (2000). Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology 150, 15–23.CrossRefGoogle ScholarPubMed
Vernon, AC, Natesan, S, Crum, WR, Cooper, JD, Modo, M, Williams, SC, Kapur, S (2012). Contrasting effects of haloperidol and lithium on rodent brain structure: magnetic resonance imaging study with postmortem confirmation. Biological Psychiatry 71, 855–863.Google Scholar
Vieta, E, Cruz, N (2012). Head to head comparisons as an alternative to placebo-controlled trials. European Neuropsychopharmacology 22, 800–803.Google Scholar
Vieta, E, Langosch, JM, Figueira, ML, Souery, D, Blasco-Colmenares, E, Medina, E, Moreno-Manzanaro, M, Gonzalez, MA, Bellivier, F (2013). Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd). International Journal of Neuropsychopharmacology 16, 1719–1732.CrossRefGoogle ScholarPubMed
Woo, G, Tomlinson, G, Nishikawa, Y, Kowgier, M, Sherman, M, Wong, DK, Pham, B, Ungar, WJ, Einarson, TR, Heathcote, EJ, Krahn, M (2010). Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: systematic review and Bayesian meta-analysis. Gastroenterology 139, 1218–1229.Google Scholar
Yildiz, A, Guleryuz, S, Ankerst, DP, Ongür, D, Renshaw, PF (2008). Protein kinase C inhibition in the treatment of mania: double-blind, placebo-controlled trial of tamoxifen. Archives of General Psychiatry 65, 255–263.Google Scholar
Yildiz, A, Undurraga, J, Vieta, E, Popovic, D, Wooderson, S, Young, A (in press a). Strategies for improving randomized trial evidence in treatment of bipolar disorder. In Bipolar Book: History, Neurobiology, and Treatment (ed. Yildiz, A., Nemeroff, C. and Ruiz, P.). Oxford University Press: New York.Google Scholar
Yildiz, A, Vieta, E, Correll, CU, Nikodem, M, Baldessarini, RJ (in press b). Critical issues on use of network meta-analysis in psychiatry. Harvard Review of Psychiatry.Google Scholar
Yildiz, A, Vieta, E, Leucht, S, Baldessarini, RJ (2011 a). Efficacy of antimanic treatments: meta-analysis of randomized controlled trials. Neuropsychopharmacology 36, 375–389.Google Scholar
Yildiz, A, Vieta, E, Tohen, M, Baldessarini, RJ (2011 b). Factors modifying drug and placebo responses in randomized trials for acute mania. International Journal of Neuropsychopharmacology 14, 863–875.CrossRefGoogle Scholar
Young, RC, Biggs, JT, Ziegler, VE, Meyer, DA (1978). Rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 133, 429–435.Google Scholar
Zarate, CA Jr., Singh, JB, Carlson, PJ, Quiroz, J, Jolkovsky, L, Luckenbaugh, DA, Manji, HK (2007). Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disorders 9, 561–570.Google Scholar
Supplementary material: File

Yildiz Supplementary Material

Appendix 1

Download Yildiz Supplementary Material(File)
File 38.4 KB
Supplementary material: File

Yildiz Supplementary Material

Appendix 2

Download Yildiz Supplementary Material(File)
File 42.8 KB
Supplementary material: File

Yildiz Supplementary Material

Appendix 3

Download Yildiz Supplementary Material(File)
File 93.6 KB
Supplementary material: File

Yildiz Supplementary Material

Appendix 4

Download Yildiz Supplementary Material(File)
File 30.5 KB